Jeremy Robert Wortman MD, Presenter: Nothing to Disclose

Sreeharsha Tirumani MBBS, MD, Abstract Co-Author: Nothing to Disclose

Akshay Baheti MBBS, MD, Abstract Co-Author: Nothing to Disclose

Michael Hayden Rosenthal MD, PhD, Abstract Co-Author: Nothing to Disclose

Jyothi Priya Jagannathan MD, Abstract Co-Author: Nothing to Disclose

Nikhil H. Ramaiya MD, Abstract Co-Author: Nothing to Disclose

1) Despite being radio-resistant, radiotherapy is often used in the management of non- gastrointestinal stromal tumor (GIST) soft tissue sarcomas. 2) Types of radiotherapy include external beam, intensity modulated and stereotactic body radiotherapy. 3) Radiotherapy can be used in non-GIST soft tissue sarcomas in adjuvant and neoadjuvant settings, as sole therapy, and for treatment of metastases. In GIST, radiotherapy is uncommonly used after R1 or R2 resections, inoperable tumors and with adjuvant imatinib. 4) Imaging plays a crucial role in treatment planning for radiotherapy by determining the gross tumor volume and clinical target volume and in assessing response to therapy. 5) Imaging helps in monitoring for complications such as radiation enteritis, pneumonitis and radiation-associated malignancies.

1) Overview of the multiple roles of radiation therapy in treatment of GIST and non-GIST soft tissue sarcomas. 2) Elucidate the concepts of gross tumor volume, clinical target volume and planned target volume. 3) Discuss methods in which imaging is used during the planning of radiation therapy using case based examples, including patterns of response to treatment. 4) Review the common complications of radiation therapy in soft tissue sarcomas.  

http://abstract.rsna.org/uploads/2014/14006898/14006898_x14d.pdf

Wortman, J, Tirumani, S, Baheti, A, Rosenthal, M, Jagannathan, J, Ramaiya, N, Radiation Therapy in Management of Soft Tissue Sarcomas: A Primer for Radiologists.  Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, - ,Chicago IL. http://archive.rsna.org/2014/14006898.html